How many insider trades does FilingIQ track for ENTA?

FilingIQ tracks 515 Form 4 insider transactions for ENTA (ENANTA PHARMACEUTICALS INC), covering filings from Nov 20, 2014 onwards. 6 of those were filed in the last 90 days.

Are ENTA insiders net buyers or net sellers?

Across the full Form 4 history for ENTA, 3 transactions (1%) were open-market purchases and 145 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ENTA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ENTA in?

ENANTA PHARMACEUTICALS INC (ENTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $404.09M.

ENTA insider trading

NasdaqGS Healthcare

ENANTA PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

515

Last 90 days

Buys / sells

1% / 28%

Market cap

$404.09M

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Company website: www.enanta.com

ENTA insider activity at a glance

FilingIQ has scored 515 insider transactions for ENTA since Nov 20, 2014. The most recent filing in our index is dated Mar 11, 2026.

Across the full history, 3 open-market purchases and 145 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ENTA insider trades is 57.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ENTA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ENTA?: FilingIQ tracks 515 Form 4 insider transactions for ENTA (ENANTA PHARMACEUTICALS INC), covering filings from Nov 20, 2014 onwards. 6 of those were filed in the last 90 days.
Are ENTA insiders net buyers or net sellers?: Across the full Form 4 history for ENTA, 3 transactions (1%) were open-market purchases and 145 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ENTA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ENTA in?: ENANTA PHARMACEUTICALS INC (ENTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $404.09M.

Methodology & sources

Every ENTA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.